Bio-Techne (TECH) EBIAT (2009 - 2026)

Bio-Techne has reported EBIAT for 18 years, with the latest figure at $51.0 million in Q1 2026.

• For the quarter ending Q1 2026, EBIAT rose 125.99% year-over-year to $51.0 million; the trailing twelve-month figure through Mar 2026 stood at $109.6 million (down 16.79% YoY), and the FY2025 full-year result was $73.4 million, down 56.34% from the prior year.
• EBIAT for Q1 2026 stood at $51.0 million, up from $38.0 million in the prior quarter.
• The five-year high for EBIAT was $89.7 million in Q3 2022, with the low at -$17.7 million in Q2 2025.
• Average EBIAT over 5 years is $45.7 million, with a median of $49.1 million recorded in 2024.
• Year-over-year, EBIAT surged 338.03% in 2022 and tumbled 143.55% in 2025.
• Tracing TECH's EBIAT over 5 years: stood at $50.0 million in 2022, then plunged by 45.08% to $27.5 million in 2023, then climbed by 27.03% to $34.9 million in 2024, then climbed by 8.94% to $38.0 million in 2025, then surged by 34.3% to $51.0 million in 2026.
• The last three EBIAT figures came in at $51.0 million (Q1 2026), $38.0 million (Q4 2025), and $38.2 million (Q3 2025), per Business Quant data.

Peer Comparison